Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to evaluate the efficacy (and safety) of antiviral therapy in patients with chronic hepatitis C after liver transplantation. The only approved drugs for treatment of hepatitis C are pegylated interferon and ribavirin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Clinic of Barcelona
• Collaborator: Schering-Plough
• Treatments: Interferons; Ribavirin

Criteria

Inclusion Criteria:

• Chronic hepatitis C defined by liver biopsy and presence of HCV-RNA

• More than 6 months from liver transplantation

• Written inform consent

Exclusion Criteria:

• Severe hepatitis C recurrence (F3-F4 fibrosis stage, cholestatic hepatitis)

• Double liver-kidney transplantation

• Leucopenia (2000) or thrombocytopenia (40.000)

• Anemia (Hemoglobin lower than 10 g/dL)

• Renal failure (creatinine > 2 mg/dL)

• Autoimmune disease

• All contraindications for interferon and ribavirin therapy